First Time Dual Chamber Pacemaker Implantation Clinical Trial
Official title:
Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker
| Verified date | April 2023 |
| Source | Medical University of Silesia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Dual chamber pacing is known to induce left ventricle remodeling and may eventually lead to heart failure. The investigators aim to test hypothesis that valsartan started immediately after dual chamber pacemaker implantation will prevent left ventricle remodeling in twelve months long follow up in comparison with placebo. Echocardiographic assessment of left ventricle remodeling will be correlated with plasma activity of matrix metalloproteinases and their tissue inhibitors, indices of functional capacity such as plasma level of NTproBNP and distance in meters during six minute walking test.
| Status | Terminated |
| Enrollment | 88 |
| Est. completion date | January 31, 2019 |
| Est. primary completion date | January 31, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - informed written consent - age = 18 years - first time pacemaker implantation for trifascicular block, atrioventricular second or third degree block - left ventricle ejection fraction = 40% Exclusion Criteria: - significant valvular heart disease - ischaemic heart disease requiring further revascularization - symptomatic hypotension - orthostatic disorders - pregnancy, breast feeding, child bearing potential - previous use of angiotensin receptor blocking agents - known hypersensitivity to valsartan - significant liver disorders - significant renal disorders, including renal artery stenosis - hyperaldosteronism - chronic use of nonsteroid antiinflammatory drugs - chronic use of lithium salts - Patient's reluctance or disability to obey protocol and/or follow the scheduled visits - any significant disease to reduce the expected life duration < 12 months - participation in any other trial within the last 30 days before randomization - any situation that would put more risk on patient |
| Country | Name | City | State |
|---|---|---|---|
| Poland | II Dept. of Cardiology in Zabrze Medical University of Silesia | Zabrze | Upper Silesia |
| Lead Sponsor | Collaborator |
|---|---|
| Medical University of Silesia | Polpharma Pharmaceutical Company |
Poland,
Garcia RA, Brown KL, Pavelec RS, Go KV, Covell JW, Villarreal FJ. Abnormal cardiac wall motion and early matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1080-7. doi: 10.1152/ajpheart.00860.2004. Epub 2004 Oct 14. — View Citation
Miyazaki S, Kasai T, Miyauchi K, Miyazaki T, Akimoto Y, Takagi A, Aihara K, Kawamura M, Suwa S, Kojima S, Sumiyoshi M, Daida H. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J. 2010 Jun;74(6):1158-64. doi: 10.1253/circj.cj-09-0412. Epub 2010 Apr 6. — View Citation
Suzuki H, Geshi E, Nanjyo S, Nakano H, Yamazaki J, Sato N, Tanaka K, Takano T, Yagi H, Shibata T, Mochizuki S, Katagiri T. Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study. Circ J. 2009 May;73(5):918-24. doi: 10.1253/circj.cj-08-0959. Epub 2009 Apr 2. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | change in echocardiographically assessed left ventricle dimensions and left ventricle function | baseline and 12 months | ||
| Secondary | change in plasma level of matrix metalloproteinase 9 | baseline and 12 months | ||
| Secondary | change in plasma level of NTproBNP | baseline and 12 months | ||
| Secondary | change in atrial arrhythmia burden assessed from pacemaker memory | baseline and 12 months | ||
| Secondary | change in the rate of occurrence of any major adverse cardiovascular event | 2 weeks, 3 months, 6 months, 9 months and 12 months | ||
| Secondary | change in plasma level of tissue necrosis factor alpha | baseline and 12 months | ||
| Secondary | change in plasma level of tissue inhibitor of matrix metalloproteinase 3 | baseline and 12 months | ||
| Secondary | change in distance walked during six minute walking test | baseline and 12 months |